drugset

drugset / Trial / NCT06052748

A Study to Evaluate the Efficacy and Safety of AD-223

NCT06052748 ↗

Phase 3 Completed 502 enrolled Addpharma Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of AD-223

Timeline

Start: 2024-02-15
Primary completion: 2025-03-27
Completion: 2025-04-02

Publications

Ahn HS, Ahn JC, Cho JM, Lim KH, Han SH, Cho YK, Kim KH, Hong SJ, Lee CJ, Na JO, Sung KC, Choi K, Kim SY, Kim DH, Lee HC, Ihm SH, Youn JC, Choi JY, Kim SH, Kim KI, Sung JH, Pyun WB, Kim WS, Cho JS, Lee Y, Her SH, Cho EJ, Lee EM, Lee HY, Yoon YW, Lee JH, Kim W, Rhee SJ, Shin J. Low-Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial. J Clin Hypertens (Greenwich). 2026 May;28(5):e70279. doi: 10.1111/jch.70279.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Amlodipine	Other / unclassified	2.5 mg	Oral
Comparator	Telmisartan	Other / unclassified	20 mg	Oral
Comparator	Telmisartan	Other / unclassified	40 mg	Oral

Indications